financetom
Business
financetom
/
Business
/
--Street Color: Boeing Outlook Revised to Negative by S&P Global Ratings
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
--Street Color: Boeing Outlook Revised to Negative by S&P Global Ratings
Apr 25, 2024 9:02 AM

11:40 AM EDT, 04/25/2024 (MT Newswires) -- (Street Color news is derived from real time discussions with market professionals globally subscribed to the Street Color Premium Chat service on Bloomberg IB Chat and the ICE IM. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Price: 161.80, Change: -2.54, Percent Change: -1.54

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
White House's Hassett says US could take stakes in other chip companies
White House's Hassett says US could take stakes in other chip companies
Aug 25, 2025
WASHINGTON, Aug 25 (Reuters) - The federal government could take stakes in other U.S. semiconductor companies or even move to other industries, White House economic adviser Kevin Hassett told CNBC in an interview on Monday following its stake in Intel ( INTC ). Hassett, asked if the Intel ( INTC ) deal was the start of a larger effort by...
BRIEF-Forager Capital Management Submits Fully Financed Proposal To Acquire Quipt Home Medical
BRIEF-Forager Capital Management Submits Fully Financed Proposal To Acquire Quipt Home Medical
Aug 25, 2025
Aug 25 (Reuters) - Quipt Home Medical Corp ( QIPT ): * FORAGER CAPITAL MANAGEMENT SUBMITS FULLY FINANCED PROPOSAL TO ACQUIRE QUIPT HOME MEDICAL FOR $3.10 PER SHARE IN CASH * QUIPT HOME MEDICAL CORP ( QIPT ) - FORAGER PREPARED TO IMPROVE OFFER WITH BOARD ENGAGEMENT Source text: Further company coverage: ...
AbbVie to Buy Gilgamesh Pharmaceuticals' Bretisilocin for Up to $1.2 Billion
AbbVie to Buy Gilgamesh Pharmaceuticals' Bretisilocin for Up to $1.2 Billion
Aug 25, 2025
09:26 AM EDT, 08/25/2025 (MT Newswires) -- AbbVie ( ABBV ) has agreed to buy Gilgamesh Pharmaceuticals' lead asset bretisilocin for up to $1.2 billion, including an upfront payment and development milestones, the companies said Monday. As part of the deal, Gilgamesh will spin off an entity to be called Gilgamesh Pharma to hold its employees and other programs, including...
Bank7 Renews Stock Buyback Plan
Bank7 Renews Stock Buyback Plan
Aug 25, 2025
09:26 AM EDT, 08/25/2025 (MT Newswires) -- Bank7 ( BSVN ) said Monday the board has renewed its stock buyback plan for a two-year term. The company said the plan provides for the purchase of up to 750,000 outstanding common shares. ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved